Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 18 2023 - 4:05PM
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision
medicine company transforming the drug discovery process by
combining leading-edge computational and experimental technologies,
today announced that data for RLY-4008 (lirafugratinib) in patients
with advanced FGFR2-altered solid tumors outside of
cholangiocarcinoma will be presented at the upcoming AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer
Therapeutics, taking place October 11-15, 2023.
Details of the oral presentation are as
follows:Title: Clinical activity of lirafugratinib
(RLY-4008), a highly selective FGFR2 inhibitor, in patients with
advanced FGFR2-altered solid tumors: the ReFocus
studyConcurrent Session 3: The Future of Tumor
Agnostic Drug DevelopmentDate/Time: Thursday,
October 12, 4:05 – 4:25 p.m. ET
The conference website indicates that full abstracts will be
available for registrants via the conference app on October 4,
2023, at 12:00 p.m. ET.
Relay Therapeutics will host a conference call to
discuss these data. Details will be provided at a future date and
available on our website under Events in the News & Events
section through the following link:
https://ir.relaytx.com/news-events/events-presentations.
The presentation will be available at the start of the session
on the company’s website at https://relaytx.com/publications/.
About RLY-4008 (lirafugratinib)
RLY-4008 (lirafugratinib) is a potent, selective and oral small
molecule inhibitor of FGFR2, a receptor tyrosine kinase that is
frequently altered in certain cancers. FGFR2 is one of four members
of the FGFR family, a set of closely related proteins with highly
similar protein sequences and properties. Preclinically, RLY-4008
demonstrated FGFR2-dependent killing in cancer cell lines and
induced regression in in vivo models, while minimal inhibition of
other targets was observed, including other members of the FGFR
family. In addition, RLY-4008 demonstrated strong activity against
known clinical on-target resistance mutations in cellular and in
vivo preclinical models. RLY-4008 is currently being evaluated in a
clinical trial in patients with advanced or metastatic
FGFR2-altered solid tumors with a single arm, potentially
registration-enabling cohort for FGFRi-naïve FGFR2-fusion CCA. To
learn more about the clinical trial of RLY-4008, please visit
here.
ReFocus Trial Background
RLY-4008 (lirafugratinib) is currently being evaluated in a
global Phase 1/2 clinical trial (ReFocus) in patients with
FGFR2-altered CCA and multiple other solid tumors including a
single arm, potentially registration-enabling cohort for
FGFRi-naïve FGFR2-fusion CCA. The Phase 1 dose escalation has been
completed, and 70 mg QD has been selected as the registrational
dose. The expansion cohorts were initiated in December 2021 and now
consist of seven different cohorts based on FGFR2 alteration and
tumor type. Of the seven cohorts, the potential pivotal cohort
consists of approximately 100 previously treated, FGFRi-naïve
FGFR2-fusion CCA patients.
About Relay Therapeutics
Relay Therapeutics is a clinical-stage precision medicine
company transforming the drug discovery process by combining
leading-edge computational and experimental technologies with the
goal of bringing life-changing therapies to patients. As the first
of a new breed of biotech created at the intersection of
complementary techniques and technologies, Relay Therapeutics aims
to push the boundaries of what’s possible in drug discovery. Its
Dynamo™ platform integrates an array of leading-edge computational
and experimental approaches designed to drug protein targets that
have previously been intractable or inadequately addressed. Relay
Therapeutics’ initial focus is on enhancing small molecule
therapeutic discovery in targeted oncology and genetic disease
indications. For more information, please visit www.relaytx.com or
follow us on Twitter.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, implied and
express statements regarding Relay Therapeutics’ strategy, business
plans and focus; the progress and timing of updates on the clinical
development of the programs across Relay Therapeutics’ portfolio,
including RLY-4008; and expected therapeutic benefits of its
programs. The words “may,” “might,” “will,” “could,” “would,”
“should,” “plan,” “anticipate,” “intend,” “believe,” “expect,”
“estimate,” “seek,” “predict,” “future,” “project,” “potential,”
“continue,” “target” and similar words or expressions are intended
to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based
on management's current expectations and beliefs and are subject to
a number of risks, uncertainties and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including, without limitation, risks associated
with: the impact of global economic uncertainty, geopolitical
instability, or public health epidemics or outbreaks of an
infectious disease, such as COVID-19, on countries or regions in
which Relay Therapeutics has operations or does business, as well
as on the timing and anticipated results of its clinical trials,
strategy, future operations and profitability; the delay of any
current or planned clinical trials or the development of Relay
Therapeutics’ drug candidates; the risk that the
preliminary results of its preclinical or clinical trials may not
be predictive of future or final results in connection with future
clinical trials of its product candidates; Relay Therapeutics’
ability to successfully demonstrate the safety and efficacy of its
drug candidates; the timing and outcome of its planned interactions
with regulatory authorities; and obtaining, maintaining and
protecting its intellectual property. These and other risks and
uncertainties are described in greater detail in the section
entitled “Risk Factors” in Relay Therapeutics’ most recent Annual
Report on Form 10-K and Quarterly Report on Form 10-Q, as well as
any subsequent filings with the Securities and Exchange Commission.
In addition, any forward-looking statements represent Relay
Therapeutics' views only as of today and should not be relied upon
as representing its views as of any subsequent date. Relay
Therapeutics explicitly disclaims any obligation to update any
forward-looking statements. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Contact:Megan
Goulart617-545-5526mgoulart@relaytx.com
Media:Dan
Budwick1AB973-271-6085dan@1abmedia.com
Relay Therapeutics (NASDAQ:RLAY)
Historical Stock Chart
From Apr 2024 to May 2024
Relay Therapeutics (NASDAQ:RLAY)
Historical Stock Chart
From May 2023 to May 2024